Anastrozole (Arimidex™) versus tamoxifen as 1st-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women -: Combined analysis from two identically designed multicenter trials

被引：0

作者：

Robertson, JFR ^{[1
]}

机构：

[1] City Hosp Nottingham, Dept Surg, Nottingham, England

来源：

BRITISH JOURNAL OF CANCER | 2000年 / 83卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P43

引用

页码：39 / 39

页数：1

共 33 条

[1] Anastrozole (AN) versus tamoxifen (TAM) as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women:: Findings highlight the importance of receptor status assessment prior to treatment initiation.
Buzdar, A
Bonneterre, J
Nabholtz, JM
Robertson, JFR
Thürlimann, B
von Euler, M
Steinberg, M
Webster, A
ANNALS OF ONCOLOGY, 2000, 11 : 25 - 25
[2] Fulvestrant ('Faslodex®') versus anastrozole ('Arimidex®') for the treatment of advanced breast cancer in postmenopausal women -: safety update on the combined analysis of two multicenter trials.
Jones, S
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 290 - 290
[3] Comment on "Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women:: survival analysis and updated safety results" By J.-M.!Nabholtz et al.
Mouridsen, HT
Chaudri-Ross, HA
EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) : 1095 - 1096
[4] Fulvestrant (Faslodex®) versus anastrozole (Arimidex®) for the treatment of advanced breast cancer:: a prospective combined survival analysis of two multicenter trials.
Pippen, J
Osborne, CK
Howell, A
Robertson, JFR
BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S101 - S101
[5] THERAPEUTIC EFFECT OF TAMOXIFEN VERSUS TAMOXIFEN COMBINED WITH MEDROXYPROGESTERONE ACETATE IN ADVANCED BREAST-CANCER IN POST-MENOPAUSAL WOMEN
MOURIDSEN, HT
ELLEMANN, K
MATTSSON, W
PALSHOF, T
DAEHNFELDT, JL
ROSE, C
CANCER TREATMENT REPORTS, 1979, 63 (02): : 171 - 175
[6] Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:: survival analysis and updated safety results
Nabholtz, JM
Bonneterre, J
Buzdar, A
Robertson, JFR
Thürlimann, B
EUROPEAN JOURNAL OF CANCER, 2003, 39 (12) : 1684 - 1689
[7] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
Bonneterre, J
Thürlimann, B
Robertson, JFR
Krzakowski, M
Mauriac, L
Koralewski, P
Vergote, I
Webster, A
Steinberg, M
von Euler, M
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3748 - 3757
[8] Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials
Robertson, JFR
Osborne, CK
Howell, A
Jones, SE
Mauriac, L
Ellis, M
Kleeberg, UR
Come, SE
Vergote, I
Gertler, S
Buzdar, A
Webster, A
Morris, C
CANCER, 2003, 98 (02) : 229 - 238
[9] Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective
Simons, R
Bassi, R
Jones, D
Barrett-Lee, P
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
[10] Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma -: Results of two randomized trials designed for combined analysis
Bonneterre, J
Buzdar, A
Nabholtz, JMA
Robertson, JFR
Thürlimann, B
von Euler, M
Sahmoud, T
Webster, A
Steinberg, M
CANCER, 2001, 92 (09) : 2247 - 2258

← 1 2 3 4 →